Suspect Stem Cell Treatments Touted for Knee Arthritis

Hundreds of clinics in the United States are selling stem cell treatments for knee osteoarthritis without solid evidence of their claims, researchers warn.

“People’s expectations have gotten ahead of the science,” said investigator George Muschler, MD, from the Cleveland Clinic, and orthopedic surgeons must be prepared to help their patients evaluate these claims.

“The quality of the literature is relatively sparse,” he told Medscape Medical News.

In a previous study that Muschler was involved in, investigators conducted a systematic review of stem cell treatments for knee osteoarthritis and focal cartilage defects of the knee, and found only four randomized controlled trials and two well-designed controlled trials without randomization (J Bone Joint Surg Am2016;98:1511-1521). The other 420 reports they identified were not well-designed trials. Although the results from the six trials were positive, the placebo effect could not be discounted, the team concludes.

This has not, however, stopped clinics from offering these treatments.

Muschler and his colleagues examined the current market for stem cell treatment for knee osteoarthritis, and presented their results here at the American Academy of Orthopaedic Surgeons (AAOS) 2018 Annual Meeting. The findings were previously published online (J Knee SurgPublished online July 24, 2017).

From October 28, 2016 to January 28, 2017, one of Muschler’s colleagues contacted 273 of 317 clinics that offer stem cell treatments for orthopedic conditions that had previously been identified (Cell Stem Cell2016;19:154-157).

Using phone or email, he presented himself as a 57-year-old patient with moderate right knee osteoarthritis, and reported a score of 6 on a 10 cm visual analog pain scale.

This “simulated patient” told clinic personnel that he had seen other orthopedic professionals who offered him pain medication and corticosteroids and told him that he would eventually need a knee replacement. He then asked how well the stem cell treatments would work for his complaint, and what the treatments would cost.

At the 65 centers that provided pricing information for a same-day stem cell unilateral knee injection, the mean cost was $5156, but prices ranged widely — from $1150 to $12,000. Muschler and his colleagues interpreted this to mean that the prices were not related to fixed costs, but rather to the amount that the clinics wanted to charge for their labor.

By Laird Harrison | Medscape

Image Credit: Laird Harrison/Medscape

READ MORE

Avatar
About Peter Coffaro 682 Articles
A growth-driven and strategic executive, Peter Coffaro commands more than 20 years of progressive management success within the orthopedic industry. Recognized by MedReps.com as one of the top medical sales influencers in the industry; he has 10 years of combined sales management experience and has held positions as a Director, General Manager and Distributor. Peter has worked for some of the top orthopedic companies in the world - Zimmer, DePuy and Stryker. He is also the founder of OrthoFeed: a popular blog that covers orthopedic news and emerging medical technologies. Peter is a three-time Hall of Fame award winner at Johnson and Johnson and has an extensive background in organizational development, business development, sales management, digital marketing and professional education. Peter holds a B.S. degree in Biology from Northern Illinois University.

Be the first to comment

Leave a Reply

Your email address will not be published.


*


This site uses Akismet to reduce spam. Learn how your comment data is processed.